Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy

<table class="figure-group"><tr class="fig-image" id="a"><td><object data="https://static-preview.hindawi.com/articles/bmri/volume-2016/9846823/figures/9846823.fig.001a.svgz" name="9846823.fig.001a" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(a) </b>Progression-free survival</td></tr><tr class="fig-image" id="b"><td><object data="https://static-preview.hindawi.com/articles/bmri/volume-2016/9846823/figures/9846823.fig.001b.svgz" name="9846823.fig.001b" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(b) </b>Overall survival</td></tr></table>

<div>The AUROC for NLR: (a) PFS and (b) OS.</div>

BioMed Research International

fig1

Figure 1

Figure 1: Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy 

Figure 1 | Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy 